The Global Antibiotics Market reached USD 40.9 billion in 2022 and is projected to witness lucrative growth by reaching USD 52.2 billion by 2030. The Global Antibiotics Market is expected to exhibit a CAGR of 3.1% during the forecast period 2023-2030. The increasing number of infectious disorders, government initiatives, increasing consumptions, research grant endeavors, promising reimbursement guidelines, and market consequences like product takeoffs, product permissions, partnerships, acquisitions, alliances, and expansion, among others, are anticipated to boost the global antibiotics market growth in the forecast period.
The Global Antibiotics Market Growth is also driven by the increased consumption of antibiotics in low & middle-income countries, significant investments in R&D activities by key market players such as GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., and Pfizer Inc. among others.
Metrics |
Details |
CAGR |
3.1% |
Size Available for Years |
2021-2030 |
Forecast Period |
2023-2030 |
Data Availability |
Value (US$) |
Segments Covered |
Drug Class, Spectrum, Distribution Channel |
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
Fastest Growing Region |
Asia-Pacific |
Largest Region |
North America |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Drug Class Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For More Insights about the Market Request Free Sample
The new product developments are expected to boost the global antibiotic market growth in the forecast period. For instance, scientists have employed artificial intelligence (AI) to find a unique antibiotic that can eliminate a lethal species of superbug. The AI enabled it to constrict thousands of possible chemicals to a handful that might be tested in the laboratory. The outcome was a powerful, experimental antibiotic called abaucin, which requires additional examinations before being utilized.
Moreover, researchers altered an existent antibiotic to produce a renewed molecule that might be efficacious against Gram-negative bacteria that are drug resistant. One molecule produced by the investigators, fabimycin, demonstrated assurance in fighting over 200 Gram-negative bacteria and did not have a notable influence on the harmless bacteria usually present in the human gut microbiome.
The increasing research funding is presenting the global antibiotics market with lucrative growth opportunities in the future. For instance, in May 2022, CARB-X, a nonprofit collaboration that directs financing and expertise to corporations producing life-saving new antibiotics, vaccines, and rapid diagnostics, received around $370 million in extra funding.
The antibiotic resistance and rarer players interested in active research are anticipated to hamper the growth of the antibiotics market over the forecast period. For instance, the report, ‘The State of Innovation in Antibacterial Therapeutics’, issued by the Biotechnology Innovation Organization (BIO), emphasized the necessity for enhanced innovation in the antibiotics sector.
The Global Antibiotics Market is segmented based on drug class, spectrum, distribution channels, and region.
Owing to the increasing product filing for new cephalosporin is boosting the segment growth and is estimated to hold about 25.8% of the global antibiotics market by 2030. For instance, in December 2022, Shionogi & Co., Ltd. announced that Taiwan Shionogi & Co., Ltd., an associate of Shionogi, filed a New Drug Application (NDA) for cefiderocol, an unexplored siderophore cephalosporin antibacterial drug, to the TFDA (Taiwan Food and Drug Administration) for the cure of infections because of aerobic Gram-negative bacteria in adult individuals with narrow therapy choices, and this application has been received for review by TFDA.
Source: DataM Intelligence Analysis (2023)
Owing to the growing prevalence of infectious diseases developed healthcare systems and favorable healthcare reimbursement policies North America is estimated to hold a large share accounting for 38.7% of the total market in the forecast period. For instance, according to the October 2022 CDC report, over 7,174 new patients with TB were registered in the US in 2021.
The same authority also reported that the preponderance of TB was to be most elevated among Hispanic or Latino individuals, who accounted for approximately 30.0% of the entire TB patients registered in the nation. Likewise, according to the November 2021 article of the CDC, the common cold impacts millions of individuals in the US annually; adults have 2-3 colds annually, and kids get more.
Source: DataM Intelligence Analysis (2023)
The major global players in the antibiotics market include GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., Bayer Healthcare AG, Novartis AG, Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche AG, and Otsuka Pharmaceutical Co. Ltd among others.
The invasion of Ukraine is an approaching catastrophe for TB control across the whole province and possibly beyond. War anywhere applies the bases for outbreaks and epidemics of communicable infections from cholera in Yemen, to polio in Syria, and measles in Afghanistan.
Wars destroy healthcare infrastructure, destroy immunization programs, and restrict access to quality care. This indicates sick individuals frequently have late diagnoses, resulting in more harmful intricacies and a more significant possibility of onward transmission.
Around 3 million individuals have escaped Ukraine following Russia’s current attack. This pursues ample recent migrations from Syria, Afghanistan, and Ethiopia, all of which hold elevated MDR-TB preponderance. Such exile is pushing to question public health reactions.
By Drug Class
By Spectrum
By Distribution Channels
By Region
Why Purchase the Report?
The Global Antibiotics Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.
Target Audience 2023
$4350
$4350
$4350
$4350
$4350
$4350